Replies to post #19705 on RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Spyderboi, Concerning the artifact topic (boy you are a party pooper :o), for one thing, it definitely isn't a class effect, that's been firmly established. And these new compounds are all being screened way ahead of time for any artifact issues. They're not going to advance anything into the clinic without testing it first. I think we can safely lay that one to rest.

[enemem]

>>>As for iv admin of CX717- well so far we have only seen a significant effect at a high (oral) dose of 2.1g and then it still is somewhere between 20-50%.

The observation that first-exposure responses were consistently more robust than second-exposure responses suggests that there is some habituation going on here, either to the ampakine, to the opioid, or to the hypercapnea. I don't think it matters which, because the indication here is to protect against RD on a one-time basis, so these desensitization effects are irrelevant, essentially an experimental design flaw.

Further, in a clinical setting, the effective analgesic dose administered post-operatively may cause some respiratory depression in most patients, but doesn't lead to apnea, so the utility of an ampakine may be to upregulate respiratory networks to provide a better margin of safety post-operatively, rather than treat full-blown respiratory arrest.

Finally, this really was the wrong protocol to test respiratory depression. What was shown here was that ampakines reduced opioid-induced depression of chemosensory feedback.

Considering how bass-ackwards this whole thing was, the fact that statistical significance was obtained from an n of 7 really does lead me to think that this compound works.